126 related articles for article (PubMed ID: 21492782)
1. Changes in 2-fluoro-2-deoxy-D-glucose incorporation, hexokinase activity and lactate production by breast cancer cells responding to treatment with the anti-HER-2 antibody trastuzumab.
Cheyne RW; Trembleau L; McLaughlin A; Smith TA
Nucl Med Biol; 2011 Apr; 38(3):339-46. PubMed ID: 21492782
[TBL] [Abstract][Full Text] [Related]
2. Predicting tumour response to anti-HER1 therapy using medical imaging: a literature review and in vitro study of [18F]-FDG incorporation by breast cancer cells responding to cetuximab.
Smith TA; Cheyne RW
Br J Biomed Sci; 2011; 68(3):158-66. PubMed ID: 21950209
[TBL] [Abstract][Full Text] [Related]
3. Changes in [18F]Fluoro-2-deoxy-D-glucose incorporation induced by doxorubicin and anti-HER antibodies by breast cancer cells modulated by co-treatment with metformin and its effects on intracellular signalling.
Cooper AC; Fleming IN; Phyu SM; Smith TA
J Cancer Res Clin Oncol; 2015 Sep; 141(9):1523-32. PubMed ID: 25579456
[TBL] [Abstract][Full Text] [Related]
4. Early changes in [18F]FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions: role of the Akt-pathway, glucose transport and HIF-1α.
Fleming IN; Andriu A; Smith TA
Breast Cancer Res Treat; 2014 Apr; 144(2):241-8. PubMed ID: 24522376
[TBL] [Abstract][Full Text] [Related]
5. Colorectal tumor cells treated with 5-FU, oxaliplatin, irinotecan, and cetuximab exhibit changes in 18F-FDG incorporation corresponding to hexokinase activity and glucose transport.
Sharma RI; Smith TA
J Nucl Med; 2008 Aug; 49(8):1386-94. PubMed ID: 18632807
[TBL] [Abstract][Full Text] [Related]
6. Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters.
Smith TA; Appleyard MV; Sharp S; Fleming IN; Murray K; Thompson AM
Cancer Chemother Pharmacol; 2013 Feb; 71(2):473-80. PubMed ID: 23178956
[TBL] [Abstract][Full Text] [Related]
7. Propranolol inhibits glucose metabolism and 18F-FDG uptake of breast cancer through posttranscriptional downregulation of hexokinase-2.
Kang F; Ma W; Ma X; Shao Y; Yang W; Chen X; Li L; Wang J
J Nucl Med; 2014 Mar; 55(3):439-45. PubMed ID: 24504055
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.
McLarty K; Fasih A; Scollard DA; Done SJ; Vines DC; Green DE; Costantini DL; Reilly RM
J Nucl Med; 2009 Nov; 50(11):1848-56. PubMed ID: 19837760
[TBL] [Abstract][Full Text] [Related]
9. Glucose-6-phosphatase Expression-Mediated [
Kim MJ; Lee CH; Lee Y; Youn H; Kang KW; Kwon J; Alavi A; Carlin S; Cheon GJ; Chung JK
Mol Imaging Biol; 2019 Oct; 21(5):917-925. PubMed ID: 30719695
[TBL] [Abstract][Full Text] [Related]
10. Effects of Administered Cardioprotective Drugs on Treatment Response of Breast Cancer Cells.
Smith TA; Phyu SM; Akabuogu EU
Anticancer Res; 2016 Jan; 36(1):87-93. PubMed ID: 26722031
[TBL] [Abstract][Full Text] [Related]
11. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer.
Shah C; Miller TW; Wyatt SK; McKinley ET; Olivares MG; Sanchez V; Nolting DD; Buck JR; Zhao P; Ansari MS; Baldwin RM; Gore JC; Schiff R; Arteaga CL; Manning HC
Clin Cancer Res; 2009 Jul; 15(14):4712-21. PubMed ID: 19584166
[TBL] [Abstract][Full Text] [Related]
12.
Dockx Y; Vangestel C; De Bruycker S; Van den Wyngaert T; Huizing M; Staelens S; Stroobants S
Cancer Biother Radiopharm; 2023 Feb; 38(1):51-61. PubMed ID: 36472460
[No Abstract] [Full Text] [Related]
13. [F]fluoro-2-deoxy-d-glucose incorporation by mcf-7 breast tumour cells in vitro is modulated by treatment with tamoxifen, Doxorubicin, and docetaxel: relationship to chemotherapy-induced changes in ATP content, hexokinase activity, and glucose transport.
Sharma RI; Welch AE; Schweiger L; Craib S; Smith TA
Int J Mol Imaging; 2011; 2011():874585. PubMed ID: 21490735
[TBL] [Abstract][Full Text] [Related]
14. In vivo monitoring of intranuclear p27(kip1) protein expression in breast cancer cells during trastuzumab (Herceptin) therapy.
Cornelissen B; Kersemans V; McLarty K; Tran L; Vallis KA; Reilly RM
Nucl Med Biol; 2009 Oct; 36(7):811-9. PubMed ID: 19720293
[TBL] [Abstract][Full Text] [Related]
15. Factors influencing [F-18] 2-fluoro-2-deoxy-D-glucose (F-18 FDG) uptake in melanoma cells: the role of proliferation rate, viability, glucose transporter expression and hexokinase activity.
Yamada K; Brink I; Bissé E; Epting T; Engelhardt R
J Dermatol; 2005 May; 32(5):316-34. PubMed ID: 16043894
[TBL] [Abstract][Full Text] [Related]
16. Influence of resistance to 5-fluorouracil and tomudex on [18F]‑FDG incorporation, glucose transport and hexokinase activity.
Law AA; Collie-Duguid ES; Smith TA
Int J Oncol; 2012 Jul; 41(1):378-82. PubMed ID: 22576694
[TBL] [Abstract][Full Text] [Related]
17. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
[TBL] [Abstract][Full Text] [Related]
18. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM
J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342
[TBL] [Abstract][Full Text] [Related]
19. EGF receptor stimulation shifts breast cancer cell glucose metabolism toward glycolytic flux through PI3 kinase signaling.
Jung KH; Lee EJ; Park JW; Lee JH; Moon SH; Cho YS; Lee KH
PLoS One; 2019; 14(9):e0221294. PubMed ID: 31532771
[TBL] [Abstract][Full Text] [Related]
20. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction.
Warburton C; Dragowska WH; Gelmon K; Chia S; Yan H; Masin D; Denyssevych T; Wallis AE; Bally MB
Clin Cancer Res; 2004 Apr; 10(7):2512-24. PubMed ID: 15073131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
